AER-271 is under clinical development by Aeromics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect AER-271’s likelihood of approval (LoA) and phase transition for Cerebral Edema took place on 13 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AER-271 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

AER-271 overview

AER-271 is under development for the treatment of stroke-related cerebral edema. It is administered through intravenous bolus and intravenous route. It is a prodrug of active free phenol derived phosphonic acid (AER-270). The drug candidate acts by targeting aquaporin-4 (AQP4), a water-channel protein.

Aeromics overview

Aeromics is a biopharmaceutical company that develops and markets drugs for the treatment of cerebral edema in stroke. The company is headquartered in New Haven, Connecticut, the US.

Quick View AER-271 LOA Data

Report Segments
  • Innovator
Drug Name
  • AER-271
Administration Pathway
  • Intravenous
  • Intravenous Bolus
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.